The clinical and therapeutic potential of targeting the RANKL/RANK pathway in T1D is underscored by our observation that OPG and DMB protect and enhance the function of human β cells against human T1D serum–induced cytotoxicity and that OPG can reverse T1D in NOD mice. This evidence concerns the gene TNFSF11 and type 1 diabetes mellitus.